Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical (LFCR)
NASDAQ:LFCR
LFCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.68 - $7.99
Previous CloseN/A
Volume140.23K
Average Volume (3M)298.76K
Market Cap
$215.49M
Enterprise Value$377.81M
Total Cash (Recent Filing)$5.42M
Total Debt (Recent Filing)$5.40M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 27, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding37,025,330
10 Day Avg. Volume526,910
30 Day Avg. Volume298,761
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.85
Price to Cash Flow (P/CF)-9.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.03
Enterprise Value/Ebitda-20.38
Forecast
1Y Price Target
$10.00Price Target Upside71.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Lifecore Biomedical News
---
Bulls Say, Bears Say
Bulls Say
Business DevelopmentThe company continues to work on dozens of new business development opportunities, which include significant multinational pharmaceutical representation, a marked improvement from the company’s historical pipeline.
Financial PerformanceLifecore Biomedical, Inc. delivered a generally solid third quarter result, which included better-than-expected performance in terms of adjusted EBITDA.
Operational EfficiencyThe sale of Lifecore's excess capital equipment is seen as a smart move because it provides $17 million in cash and enhances financial flexibility.
Bears Say
Cash FlowFree cash flow for the year is expected to be negative, though it is projected to break-even in the future.
Debt And LeverageLifecore has a highly leveraged balance sheet with approximately $180.1 million in debt and $44.3 million in convertible preferred stock.
Valuation ConcernsA premium valuation still seems inappropriate due to leverage and valuation concerns.
---
Ownership Overview
28.99% Insiders
6.25% Mutual Funds
48.84% Other Institutional Investors
8.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LFCR FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was $3.68 and its highest was $7.99 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Lifecore Biomedical’s market cap is $215.49M.
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is Aug 27, 2025 which is in 135 days.
How were Lifecore Biomedical’s earnings last quarter?
Lifecore Biomedical released its earnings results on Apr 03, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.32.
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Undervalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate is -0.1.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 37,025,330 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Lifecore Biomedical reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -22.32%.
Which hedge fund is a major shareholder of Lifecore Biomedical?
Currently, no hedge funds are holding shares in LFCR
---
Lifecore Biomedical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (71.82% Upside)
$10.00 (71.82% Upside)
Blogger Sentiment
Bullish
LFCR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $97.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.67%
12-Months-Change
Fundamentals
Return on Equity
-83.58%
Trailing 12-Months
Asset Growth
-3.47%
Trailing 12-Months
Company Description
Lifecore Biomedical
Lifecore Biomedical (LFCR) is a specialty pharmaceutical company that operates in the healthcare sector. It focuses on the development, manufacturing, and commercialization of complex and highly differentiated injectable pharmaceutical products. The company is known for its expertise in hyaluronic acid-based products and its capabilities in aseptic filling and formulation. Lifecore Biomedical serves various clients, including pharmaceutical and medical device companies, providing them with comprehensive solutions from product development to commercial manufacturing.
---
LFCR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strategic advancements, new partnerships, and operational improvements, but was weighed down by decreased quarterly revenue and a significant net loss. The company remains optimistic about future growth and financial recovery.Read More>---
LFCR Stock 12 Month Forecast
Average Price Target
$10.00
▲(71.82% Upside)
Technical Analysis
Emergent Biosolutions
―
Esperion
―
Aquestive Therapeutics
―
Alpha Teknova
―
Journey Medical Corp
―
Best Analysts Covering LFCR
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-2.94%
reiterated a buy rating 5 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -2.94% per trade.
---